Archiv Euromedicaジャーナルにおけるチャーガに関する記事

当社の親会社になるBaikal Herbs社の社長、Pavel Khoroshutin氏は2021年にArchiv Euromedicaという欧州の科学ジャーナルにチャーガに関する記事の著者になりました。 ( ). 記事はチャーガの健康ベネフィットのサマリーであり、既存の科学的な資料の概説になります。ご参考までにこの記事の英語要約を以下に搭載させていただきます。ご関心がありましたら、ジャーナルのサイトでフールテキストを参照してください。Archiv Euromedicaの記事アクセスは自由です。


Pavel Khoroshutin (1), Galina Reva (3), Tatsuo Yamamoto (3), Ivan Reva (3)

  1. Baikal Herbs Ltd., Science and quality management department laboratory, Irkutsk
  2. Far Eastern Federal University, Vladivostok, Russia
  3. International Medical Education and Research Center, Niigata, Japan.

ABSTRACT - The study presents an analysis of the available scientific literature and outcomes of clinical trials on biologically active components of the birch Chaga mushroom Inonotus obliquus (I. obliquus). Our experimental and clinical studies were aimed at testing a novel plant-based substance for patients with cancer or tumors of various locations. The paper investigates pathogenetic mechanisms and effectiveness of Chaga mushroom extracts depending on the topography of the tumor, the stage of the disease and the age of patients, as well as the questions of pharmacokinetics and pharmacodynamics of the components of I. obliquus. As a result of the analysis of the obtained data, the pathogenetically justified clinical application of extracts of the birch Chaga mushroom I. obliquus in patients with oncological pathology was conceptually presented. The study allowed us to reveal possible mechanisms of

pathogenetic effects of the birch Chaga mushroom (Inonotus obliquus) extracts obtained by different extraction methods. Analysis of the available data enabled us to deepen our understanding of the effectiveness and mechanisms of the effect of the I. obliquus extracts on tumors of various localization. Finally we present recommendations on predicting the possibility of using the I. obliquus to improve outcomes in patients with cancer of various etiology and locations.